1.80
0.02 (1.12%)
| Previous Close | 1.78 |
| Open | 1.74 |
| Volume | 3,211,659 |
| Avg. Volume (3M) | 2,881,115 |
| Market Cap | 128,182,232 |
| Price / Sales | 17.53 |
| Price / Book | 2.60 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Operating Margin (TTM) | -9,653.85% |
| Diluted EPS (TTM) | -0.340 |
| Quarterly Revenue Growth (YOY) | -12.20% |
| Total Debt/Equity (MRQ) | 24.34% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | -49.55 M |
| Levered Free Cash Flow (TTM) | -27.61 M |
| Return on Assets (TTM) | -31.37% |
| Return on Equity (TTM) | -36.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ovid Therapeutics Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 16.31% |
| % Held by Institutions | 55.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Affinity Asset Advisors, Llc | 30 Sep 2025 | 2,650,000 |
| Sio Capital Management, Llc | 30 Sep 2025 | 1,427,495 |
| Ikarian Capital, Llc | 30 Sep 2025 | 1,095,574 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 5.00 (Leerink Partners, 177.78%) | Buy |
| Median | 3.50 (94.44%) | |
| Low | 2.00 (HC Wainwright & Co., 11.11%) | Buy |
| Average | 3.50 (94.44%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.40 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Nov 2025 | 2.00 (11.11%) | Buy | 1.49 |
| Leerink Partners | 17 Nov 2025 | 5.00 (177.78%) | Buy | 1.30 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |